Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Perrigo Company PLC Add to portfolio

INX:PRGO, Dec 14, 10:58 UTC

Latest INX:PRGO News

Filter your feed

Apply Filter

Thursday, December 06


News

Market Trends Toward New Normal in Perrigo Company plc, Sina, Gerdau S.A, Sinclair Broadcast Group, Invesco, and Enbridge — Emerging Consolidated Expectations, Analyst Ratings

PRGO IVZ

The new research reports from Fundamental Markets, available for free download at the links above, examine Perrigo Company plc (PRGO), Sina Corporation (SINA), Gerdau S.A. (GGB), Sinclair Broadcast Group, Inc. (SBGI), Invesco Ltd. (IVZ), and Enbridge Inc (ENB) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. The report will be for the fiscal period ending December 31st, 2018. Gerdau S.A's Recent Financial Performance. For the three months ended September 30th, 2018 vs September 30th, 2017, Gerdau S.A reported revenue of $3,260.25MM vs $2,997.32MM (up 8.77%) and analysts estimated basic earnings per share $0.12 vs $0.03 (up 361.66%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Gerdau S.A reported revenue of $11,562.60MM vs $10,794.73MM (up 7.11%) and analysts estimated basic earnings per share -$0.07 vs -$0.49.

Read Full Details

Topics:
  • Business
  • Financial

Tuesday, December 04


News

Sol-Gel Technologies Announces Sixth Agreement for a Generic Product Candidate with Perrigo

PRGO

NESS ZIONA, Israel, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced it has entered into a sixth collaborative agreement with Perrigo Israel, an affiliate of Perrigo Company plc ("Perrigo") (NYSE; TASE: PRGO), for the development, manufacturing and commercialization of a generic product candidate. “This strategy first came to fruition last January when Perrigo received tentative approval from the FDA for ivermectin cream, 1%, developed in collaboration with Sol-Gel. Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statement, including but not limited to, the following: the fact that we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; our ability to complete the development of our product candidates; our ability to obtain and maintain regulatory approvals for our product candidates in our target markets and the possibility of adverse regulatory or legal actions relating to our product candidates even if regulatory approval is obtained; our ability to rely on data from our Phase II TWIN trial to advance the development of SIRS-T; our ability to commercialize our product candidates; our ability to obtain and maintain adequate protection of our intellectual property; our ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; our ability to establish adequate sales, marketing and distribution channels; acceptance of our product candidates by healthcare professionals and patients; the possibility that we may face third-party claims of intellectual property infringement; the timing and results of clinical trials that we may conduct or that our competitors and others may conduct relating to our or their products; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; potential product liability claims; potential adverse federal, state and local government regulation in the United States, Europe or Israel; and loss or retirement of key executives and research scientists.

Read Full Details

Topics:
  • Business
  • Financial
  • Health

Saturday, December 01


News

Perrigo (NYSE:PRGO) Releases Quarterly Earnings Results – Fairfield Current

PRGO

The company reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.04, Briefing.com reports. Perrigo updated its FY 2018 guidance to $4.45-4.65 EPS and its FY18 guidance to $4.45-4.65 EPS. The firm has a market cap of $8.61 billion, a P/E ratio of 12.63, a price-to-earnings-growth ratio of 2.28 and a beta of 0.66. Wells Fargo & Co reduced their price objective on Perrigo from $84.00 to $77.00 and set a “market perform” rating for the company in a research report on Tuesday, August 21st.

Read Full Details

Topics:
  • Business
  • Financial

Thursday, November 29


News

Is Buying Perrigo Company Plc Ordinary Shares (NYSE:PRGO), Having Higher Short Interest a Winning Strategy?

PRGO

It improved, as 36 investors sold Perrigo Company plc shares while 104 reduced holdings. 105.75 million shares or 2.70% more from 102.96 million shares in 2018Q1 were reported. The New Jersey-based Prudential Financial Inc has invested 0.03% in Perrigo Company plc (NYSE:PRGO). More notable recent Perrigo Company plc (NYSE:PRGO) news were published by: Benzinga.com which released: “Benzinga’s Top Upgrades, Downgrades For November 13, 2018 – Benzinga” on November 13, 2018, also 247Wallst.com with their article: “Thursday’s Biggest Winners and Losers in the S&P 500 – 24/7 Wall St.” published on November 08, 2018, Benzinga.com published: “Earnings Scheduled For November 8, 2018 – Benzinga” on November 08, 2018.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Wednesday, November 28


News

Perrigo Company PLC (NYSE:PRGO) dividends of $0.19 are projected for the near future; this is why.

PRGO

Perrigo Company PLC (NYSE:PRGO) dividends of $0.19 are projected for the near future; this is why. It improved, as 36 investors sold Perrigo Company plc shares while 104 reduced holdings. 105.75 million shares or 2.70% more from 102.96 million shares in 2018Q1 were reported. Perrigo Company plc (NYSE:PRGO) has declined 15.60% since November 28, 2017 and is downtrending.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Perrigo Announces Patent Litigation Settlement For The Generic Version Of Sernivo® Spray, 0.05%

PRGO

DUBLIN, Nov. 28, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has settled its Hatch-Waxman litigation relating to Sernivo® (betamethasone dipropionate, 0.05%) Spray brought by Promius Pharma LLC. Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan stated, "This settlement is another example of our long-term commitment and investments in our extended topicals strategy. Our R&D, operations and legal teams continue to work diligently and relentlessly to introduce new generic products that provide savings to patients and healthcare systems." Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control, including: the timing, amount and cost of any share repurchases; future impairment charges; the success of management transition; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than the Company does; pricing pressure from customers and consumers; potential third-party claims and litigation, including litigation relating to the Company's restatement of previously-filed financial information; potential impacts of ongoing or future government investigations and regulatory initiatives; resolution of uncertain tax positions; the impact of tax reform legislation and healthcare policy; general economic conditions; fluctuations in currency exchange rates and interest rates; the consummation of announced acquisitions or dispositions and the success of such transactions, and the Company's ability to realize the desired benefits thereof; and the Company's ability to execute and achieve the desired benefits of announced cost-reduction efforts and strategic initiatives and other Statements regarding the separation of the RX business, including the expected benefits, anticipated timing, form of any such separation and whether the separation ultimately occurs, are all subject to various risks and uncertainties, including future financial and operating results, our ability to separate the business, the effect of existing interdependencies with our manufacturing and shared service operations, and the tax consequences of the planned separation to the Company or its shareholders.

Read Full Details

Topics:
  • Business
  • Financial
  • Health

Tuesday, November 27


News

Perrigo Company Plc $PRGO Technical Update – Stock Traders Daily NEWS

PRGO

Our Disruptive Tactical Strategies can work regardless of market direction or economic conditions. November 26, 2018, BY Thomas H. Kee Jr - Editor, Stock Traders Daily | Subscribe to RSS. We have day, swing, and longer-term trading plans for PRGO, and 1300 other stocks too, updated in real time for our trial subscribers. The data below is a snapshot, but updates are available now.

Read Full Details

Topics:
  • Business
  • Financial

Monday, November 26


News

Perrigo Announces Tentative FDA Approval For The First To File Generic Version Of Ultravate® Lotion 0.05%

PRGO

DUBLIN, Nov. 26, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the first to file generic version of Ultravate® Lotion (halobetasol propionate) 0.05%. Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan stated, "Our R&D team continues its efforts to secure regulatory approvals for important new products. This tentative approval reflects our continued dedication to developing extended topical products for patients and further illustrates our commitment to advancing our new product pipeline." Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control, including: the timing, amount and cost of any share repurchases; future impairment charges; the success of management transition; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than the Company does; pricing pressures from customers and consumers; potential third-party claims and litigation, including litigation relating to the Company's restatement of previously-filed financial information; potential impacts of ongoing or future government investigations and regulatory initiatives; resolution of uncertain tax positions; the impact of U.S. tax reform legislation and healthcare policy; general economic conditions; fluctuations in currency exchange rates and interest rates; the consummation of announced acquisitions or dispositions and the success of such transactions, and the Company's ability to realize the desired benefits thereof; and the Company's ability to execute and achieve the desired benefits of announced cost-reduction efforts and other initiatives.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Saturday, November 24


News

Perrigo Target of Unusually High Options Trading (NYSE:PRGO) – Marea Informative

PRGO

Perrigo Company PLC (NYSE:PRGO) was the recipient of unusually large options trading on Thursday. Wells Fargo & Co lowered their price target on Perrigo from $84.00 to $77.00 and set a “market perform” rating on the stock in a research report on Tuesday, August 21st. Over the last quarter, insiders have bought 25,783 shares of company stock valued at $1,646,976. Victory Capital Management Inc. now owns 3,136,381 shares of the company’s stock valued at $222,056,000 after purchasing an additional 334,660 shares during the last quarter.

Read Full Details

Topics:
  • Business
  • Financial
News

Perrigo (PRGO) Releases FY18 Earnings Guidance – PressOracle

PRGO

The company issued revenue guidance of ~$4.72 billion, compared to the consensus revenue estimate of $4.87 billion.Perrigo also updated its FY 2018 guidance to $4.45-4.65 EPS. Perrigo has a 1 year low of $59.88 and a 1 year high of $95.93. On average, equities research analysts expect that Perrigo will post 4.55 earnings per share for the current fiscal year. Deutsche Bank cut Perrigo from a buy rating to a hold rating and reduced their target price for the stock from $93.00 to $78.00 in a report on Friday, August 10th.

Read Full Details

Topics:
  • Business
  • Financial